With Pipeline of Syndromic Tests, Qorvo Eyes Emergence as More Than a COVID Company
Article By Greg Cima / April 25, 2023
Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
News
Leaders of Life Sciences – How Leadership Must Evolve As Companies Scale
In this conversation, Stan Glazer, Managing Director at Outcome, shares insights from his extensive experience in the life sciences industry.
Read MoreResources
Outcome Capital Life Science Market Pulse, April 2025
Outcome Capital Life Science Market Pulse April 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
